HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy

Oncotarget

Volumn 5, Issue 20, 2014, Pages 9980-9991

  Nagaraju, Ganji Purnachandra ^a   Alese, Olatunji B ^a   Landry, Jerome ^b   Diaz, Roberto ^c   El Rayes, Bassel F ^a  

^a Department of Hematology and Medical Oncology ^*  (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cell cycle progression and chemotherapy; Colon cancer; Ganetespib; Hsp90

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GANETESPIB; HEAT SHOCK PROTEIN 90; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P21; RAF PROTEIN; SOMATOMEDIN; STRESS ACTIVATED PROTEIN KINASE; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; PLATINUM COMPLEX; SMALL INTERFERING RNA; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIZATION; ENZYME INHIBITION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DRUG POTENTIATION; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; HCT116 CELL LINE; HT 29 CELL LINE; METABOLISM; MOLECULARLY TARGETED THERAPY; NUDE MOUSE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE PROTEINS; COLORECTAL NEOPLASMS; DOWN-REGULATION; DRUG SYNERGISM; FEMALE; FLUOROURACIL; HCT116 CELLS; HSP90 HEAT-SHOCK PROTEINS; HT29 CELLS; HUMANS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; ORGANOPLATINUM COMPOUNDS; RNA, SMALL INTERFERING; THYMIDYLATE SYNTHASE; TRANSFECTION; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928971834     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2484     Document Type: Article

References (48)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013; 63(1):11-30.
2. Midgley R, Kerr D. Already Registered? Please Login. The Lancet. 1999; 353(9150):391-399.
3. Thirion P, Wolmark N, Haddad E, Buyse M, Piedbois P. Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: A re-analysis of 1458 non-operable patients randomised in 22 trials and 4 metaanalyses. Annals of oncology. 1999; 10(11):1317-1320.
4. Peters G, Backus H, Freemantle S, Van Triest B, Codacci-Pisanelli G, Van der Wilt C, Smid K, Lunec J, Calvert A, Marsh S. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2002; 1587(2):194-205.
5. Roukos DH, Katsios C, Liakakos T. Genotypephenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert review of molecular diagnostics. 2010; 10(5):541-545.
6. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New England journal of medicine. 2004; 351(4):337-345.
7. Karapetis CS, Price TJ. Resistance to EGF receptortargeted monoclonal antibodies in the management of advanced colorectal cancer. Colorectal Cancer. 2012; 1(2):137-148.
8. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, Vogelstein B. Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987; 327(6120):293-297.
9. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002; 418(6901):934-934.
10. Maughan T, Adams R, Smith C, Seymour M, Wilson R, Meade A, Fisher D, Madi A, Cheadle J, Kaplan R. Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): Mature results of the MRC COIN trial. J Clin Oncol. 2010; 28(15S):3502.
11. Chen J, Huang XF, Katsifis A. Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer. Journal of cellular biochemistry. 2010; 111(5):1082-1086.
12. Kaulfub S, Burfeind P, Gaedcke J, Scharf J-G. Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. Molecular cancer therapeutics. 2009; 8(4):821-833.
13. Stepanova L, Finegold M, DeMayo F, Schmidt EV, Harper JW. The Oncoprotein Kinase Chaperone CDC37 Functions as an Oncogene in Mice and Collaborates with Both c-mycand Cyclin D1 in Transformation of Multiple Tissues. Molecular and cellular biology. 2000; 20(12):4462-4473.
14. Murillo G, Salti G, Kosmeder Ii J, Pezzuto J, Mehta R. Deguelin inhibits the growth of colon cancer cells through the induction of apoptosis and cell cycle arrest. European Journal of Cancer. 2002; 38(18):2446-2454.
15. Ramana KV, Tammali R, Srivastava SK. Inhibition of Aldose Reductase Prevents Growth Factor-Induced G1-S Phase Transition through the AKT/Phosphoinositide 3-Kinase/E2F1 Pathway in Human Colon Cancer Cells. Molecular cancer therapeutics. 2010; 9(4):813-824.
16. Stanelle J, Stiewe T, Theseling CC, Peter M, Pützer BM. Gene expression changes in response to E2F1 activation. Nucleic acids research. 2002; 30(8):1859-1867.
17. Kasahara M, Takahashi Y, Nagata T, Asai S, Eguchi T, Ishii Y, Fujii M, Ishikawa K. Thymidylate synthase expression correlates closely with E2F1 expression in colon cancer. Clinical cancer research. 2000; 6(7):2707-2711.
18. Leichman CG, Lenz H-J, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M, Danenberg PV. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. Journal of clinical oncology. 1997; 15(10):3223-3229.
19. Goetz M, Toft D, Ames M, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Annals of oncology. 2003; 14(8):1169-1176.
20. Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Molecular cancer therapeutics. 2012; 11(2):475-484.
21. Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clinical cancer research. 2013; 19(11):3068-3077.
22. Mateyak MK, Obaya AJ, Sedivy JM. c-Myc regulates cyclin D-Cdk4 and-Cdk6 activity but affects cell cycle progression at multiple independent points. Molecular and cellular biology. 1999; 19(7):4672-4683.
23. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends in cell biology. 2003; 13(2):65-70.
24. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J-y, Livingston DM. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell. 1993; 73(3):487-497.
25. Nevins JR. The Rb/E2F pathway and cancer. Human Molecular Genetics. 2001; 10(7):699-703.
26. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-674.
27. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on cancer stage IV colon adenocarcinoma. Cancer. 2001; 92(5):1331-1346.
28. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G, Samuel S, Kim MP, Lim SJ, Ellis LM. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer research. 2009; 69(5):1951-1957.
29. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. The lancet oncology. 2010; 11(8):753-762.
30. Fernández-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes & cancer. 2011; 2(3):344-358.
31. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nature reviews Clinical oncology. 2009; 6(9):519-527.
32. Van Cutsem E, Köhne C-H, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Journal of Clinical Oncology. 2011:JCO. 2010.2033. 5091.
33. Thoms HC, Dunlop MG, Stark LA. p38-mediated inactivation of cyclin D1/cyclin-dependent kinase 4 stimulates nucleolar translocation of RelA and apoptosis in colorectal cancer cells. Cancer research. 2007; 67(4):1660-1669.
34. Bernards R. Cancer: entangled pathways. Nature. 2008; 455(7212):479-480.
35. Nagaraju GP, Long T, Park W, Landry J, Taliaferro-Smith L, Alton BF, Diaz R, El-Rayes B. Heat shock protein 90 promotes epithelial to mesenchymal transition, invasion and migration in colorectal cancer. Molecular Carcinogenesis. (In press).
36. Goldman JW, Raju RN, Gordon GA, El-Hariry I, Teofilivici F, Vukovic VM, Bradley R, Karol MD, Chen Y, Guo W. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the HSP90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC cancer. 2013; 13(1):152.
37. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA, Allegra CJ. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. Journal of clinical oncology. 1994; 12(12):2640-2647.
38. Johnston PG, Lenz H-J, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer research. 1995; 55(7):1407-1412.
39. Hu YC, Komorowski RA, Graewin S, Hostetter G, Kallioniemi O-P, Pitt HA, Ahrendt SA. Thymidylate synthase expression predicts the response to 5-fluorouracilbased adjuvant therapy in pancreatic cancer. Clinical cancer research. 2003; 9(11):4165-4171.
40. Johnston PG, Behan KA, Allegra CJ, Mick R, Dolan ME, Ratain MJ, Recant W, Weichselbaum RR, Vokes EE, Beckmann E. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. Journal of the National Cancer Institute. 1997; 89(4):308-313.
41. Berger SH, Barbour KW, Berger FG. A naturally occurring variation in thymidylate synthase structure is associated with a reduced response to 5-fluoro-2'- deoxyuridine in a human colon tumor cell line. Molecular pharmacology. 1988; 34(4):480-484.
42. Friedland JC, Smith DL, Sang J, Acquaviva J, He S, Zhang C, Proia DA. Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes. Investigational new drugs. 2014; 32(1):14-24.
43. Lee KH, Lee JH, Han SW, Im SA, Kim TY, Oh DY, Bang YJ. Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins. Cancer science. 2011; 102(7):1388-1395.
44. Nagaraju GP, Park W, Wen J, Mahaseth H, Landry J, Farris AB, Willingham F, Sullivan PS, Proia DA, El-Hariry I. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1a and STAT-3. Angiogenesis. 2013; 16(4):903-917.
45. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England journal of medicine. 2004; 350(23):2335-2342.
46. Joulain F, Van Cutsem E, Usman I, Hoyle M and Allegra C. Aflibercept versus placebo in combination with FOLFIRI in previously treated metastatic colorectal cancer (mCRC): Mean overall survival (OS) estimation from a phase III trial (VELOUR). J Clin Oncol. 2012; 30(15 Suppl):3602.
47. Moser C, Lang SA, Kainz S, Gaumann A, Fichtner-Feigl S, Koehl GE, Schlitt HJ, Geissler EK and Stoeltzing O. Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo. Molecular cancer therapeutics. 2007; 6(11):2868-2878.
48. Cercek A, Shia J, Gollub M, Raasch P and Hollywood E. Phase II study of ganetespib, an hsp-90 inhibitor, in patients with refractory metastatic colorectal cancer. J Clin Oncol. 2012; 30:467.